We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
On the heels of a pre-IND meeting with the FDA, Carmell Therapeutics said it is significantly advancing the company's clinical and regulatory strategies driving the company's need to expand its manufacturing facilities.